SGFG
ACAD icon

Silver Grove Financial Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Silver Grove Financial Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152 Buy
+6
New +$132 ﹤0.01% 2274

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Silver Grove Financial Group's ACAD Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 6 shares worth $152. The stake represents ﹤0.01% of the portfolio and ranks #2274 among its holdings.

352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Silver Grove Financial Group held 6 shares of Acadia Pharmaceuticals worth $152 as of Q2 2026.
  • Acadia Pharmaceuticals was a new Silver Grove Financial Group position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2274 holding.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.